Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib + Chemotherapy in EGFR+ NSCLC
NCT03992885Phase 3Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of icotinib in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Progress free survival at 5 years and Overall survival at 5 years. Status: unknown.
02
Drugs
icotinib
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03992885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992885.